Zoll’s RescueNet 12-Lead is a free and versatile transmission system that allows healthcare providers to receive and ...
Angioslide announced the closing of $6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments to complete the round.
The results of a recent study presented yesterday at the American Heart Association Scientific Sessions 2012 conference in Los Angeles showed that a high-quality single-lead ECG can be quickly and easily recorded using an iPhone with the AliveCor medical device and application to diagnose atrial fibrillation (AF).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
CardiAQValve Technologies Inc. received $37.3 million in funding in its second round of equity financing. OrbiMed led the round and was joined by Versant Ventures, Advent Life Sciences and existing investors. The funding, which incorporates conversion of a 2011 bridge financing, will be used to further validate the company’s transcatheter mitral valve implantation (TMVI) technology and is expected to carry the company through its feasibility and CE mark clinical trials. Concurrent with the financing, David Bonita, M.D., and Vince Burgess have joined the board of directors representing OrbiMed.
Spectranetics Corp. announced an agreement to purchase the assets of Upstream Peripheral Technologies Ltd., an affiliate of Aran Research Development and Prototypes Ltd. Included in the acquisition are unique technologies that expand Spectranetics' vascular intervention portfolio. A full launch in the United States and Europe will occur in February 2013.
Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The randomized controlled trial will enroll about 2,250 patients and compare the performance of Abbott's drug-eluting Absorb boresorbable vascular scaffold (BVS) device to the company's Xience family of drug-eluting stents.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
At RSNA 2012, GE Healthcare announced a first-of-its-kind agreement with the University of Wisconsin (UW) School of Medicine and Public Health for the purpose of providing physicians with more tools to optimize radiation dose, take clinically-useful images, and potentially reduce the frequency of repeat computed tomography (CT) scans.
Biosensors International has announced enrollment of the first patient in LEADERS FREE, a clinical study involving BioFreedom, a polymer-free drug-coated stent (DCS) from Biosensors.
Fovia Medical Inc. and Blackford Analysis Ltd. announced plans to deliver compatible SDKs to the medical advanced visualization market.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Accumetrics Inc. announced that its next generation VerifyNow II System has achieved CE marking for point-of-care measurement of platelet reactivity to antiplatelet agents. This marks the culmination of a series of important milestones in 2012, increasing evidence of the clinical value of platelet reactivity testing and significantly expanding the market opportunities for the VerifyNow System in both surgical and interventional cardiology patient populations.
Biotronik announced that the European Heart Journal has published the clinical results of the ECOST trial (Effectiveness and Cost of ICD Follow-Up Schedule with Telecardiology). The randomized controlled study evaluated the safety and efficacy of Biotronik Home Monitoring compared with standard in-office follow-up visits for patients with implantable cardioverter-defibrillators (ICDs).
January 3, 2013 — Cardiovascular Systems Inc. (CSI) announced it has completed enrollment in its ORBIT II clinical trial, enrolling 443 patients. ORBIT II is evaluating the safety and effectiveness of the company’s orbital atherectomy technology in treating severely calcified coronary arteries.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
January 3, 2013 — BioVentrix announced it has received CE mark for its Revivent myocardial anchoring system, which makes possible Less Invasive Ventricular Enhancement (LIVE), a procedure that restores the left ventricle from damage done by a heart attack to a more optimal volume and conical shape.
Miracor Medical Systems GmbH announced that its PICSO system was used for the first time under CE mark in the United Kingdom to treat a patient with a large acute heart attack, or ST-segment elevation myocardial infarction (STEMI). Interventional cardiologist Dr. Magdi El-Omar performed the PICSO procedure in Manchester, England.
Tensys Medical Inc has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TL-300, the company’s latest generation system. The TL-300 is a member of Tensys’ established T-Line family, which has successfully been used by over 50,000 patients since commercial launch. The T-Line technology accurately and continuously captures a patient’s beat-to-beat waveform and blood pressure in a completely noninvasive fashion, providing physicians with a stream of real-time hemodynamic data that is not possible using traditional noninvasive blood pressure (cuff) devices. Avoiding the blind-time associated with a deflated or inaccurate cuff can enhance hemodynamic monitoring, which has been definitively linked to improved clinical outcomes.